Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024
November 27, 2023 08:30 ET
|
Biomea Fusion, Inc.
New clinical data from all dosing cohorts (n=62) initiated to date from the escalation portion of COVALENT-111 and long-term (26 weeks) follow-up data of the 200 mg dosed cohorts will be featured...
Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
November 16, 2023 08:30 ET
|
Biomea Fusion, Inc.
New clinical data providing long-term 26 weeks follow-up of the initial two dosing cohorts of COVALENT-111 will be presented during the Abstract Oral Presentation Session at WCIRDC meeting on Friday,...
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
November 08, 2023 16:05 ET
|
Biomea Fusion, Inc.
An abstract, “BMF-219: A novel therapeutic agent to reestablish functional beta cells and provide long-term glycemic control” will be presented during the WCIRDC meeting held in Los Angeles, December...
Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023
November 02, 2023 09:05 ET
|
Biomea Fusion, Inc.
First presentation of clinical data from ongoing COVALENT-101 trial of covalent menin inhibitor BMF-219 as a treatment for patients with liquid tumorsTrial in progress presentation featuring study...
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
October 30, 2023 16:01 ET
|
Biomea Fusion, Inc.
Demonstrated durable HbA1c lowering in the escalation portion of ongoing Phase II study in type 2 diabetes (COVALENT-111), with 84% of all patients showing a reduction of HbA1c after 4 weeks dosing...
Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)
October 17, 2023 08:30 ET
|
Biomea Fusion, Inc.
BMF-500, a novel 3rd generation oral covalent inhibitor of FMS-like tyrosine kinase 3 (FLT3), is the second product candidate discovered and developed by Biomea’s proprietary FUSION™ System to enter...
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes
October 05, 2023 08:30 ET
|
Biomea Fusion, Inc.
The FDA has cleared the initiation of COVALENT-112, a Phase II clinical trial of BMF-219 in adults with type 1 diabetes (T1D).The randomized, double-blind, placebo-controlled (N=150) trial in adults...
Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study
September 28, 2023 08:30 ET
|
Biomea Fusion, Inc.
The FDA and Health Canada have cleared the initiation of the expansion portion of COVALENT-111, which will evaluate BMF-219 administered at 100 mg and 200 mg, with dosing durations up to 12 weeks in...
Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer
August 31, 2023 08:30 ET
|
Biomea Fusion, Inc.
Industry veteran and prominent diabetes clinical development expert to oversee Biomea’s progressing clinical development of novel covalent menin inhibitor BMF-219 in type 2 and type 1 diabetesSteve...
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
July 31, 2023 16:01 ET
|
Biomea Fusion, Inc.
Reported additional positive clinical data at ADA 83rd Scientific Sessions from the first two cohorts of patients with type 2 diabetes from ongoing Phase I/II study (COVALENT-111) evaluating BMF-219...